Hemogenyx Pharmaceuticals Plc (GB:HEMO) has released an update.
Hemogenyx Pharmaceuticals Plc, a biopharmaceutical company focused on developing treatments for blood diseases, has announced significant progress with the submission and subsequent FDA approval to commence Phase I clinical trials of HEMO-CAR-T for acute myeloid leukemia. Alongside this, the company has raised over £8 million through share issuances to support its clinical trials and continued development of its Chimeric Bait Receptor platform, which shows potential for treating a wide range of viral diseases and cancers. The financial year ended with a reported loss of £6.7 million, attributed to operational expenses and development costs.
For further insights into GB:HEMO stock, check out TipRanks’ Stock Analysis page.
